Home/Filings/4/0001209191-12-031979

4//SEC Filing

STEINMETZ MICHAEL 4

Accession 0001209191-12-031979

CIK 0001339455other

View on SEC.gov Company Profile

Filed

Jun 3, 8:00 PM ET

Accepted

Jun 4, 4:54 PM ET

Size

24.4 KB

Accession

0001209191-12-031979

Insider Transaction Report

Form 4

Period: 2012-05-22

Somaxon Pharmaceuticals, Inc.SOMX

GALAKATOS NICHOLAS

10% Owner

Transactions

Sale
Common Stock
2012-05-31$0.30/sh−29,850$8,955→ 3,821,140 total(indirect: See Footnote)
Sale
Common Stock
2012-05-22$0.30/sh−287,000$86,990→ 4,345,562 total(indirect: See Footnote)
Sale
Common Stock
2012-05-23$0.30/sh−135,250$40,629→ 4,210,312 total(indirect: See Footnote)
Sale
Common Stock
2012-05-30$0.30/sh−51,007$15,302→ 3,850,990 total(indirect: See Footnote)
Sale
Common Stock
2012-05-25$0.30/sh−293,015$87,905→ 3,917,297 total(indirect: See Footnote)
Sale
Common Stock
2012-05-29$0.30/sh−15,300$4,622→ 3,901,997 total(indirect: See Footnote)

HENNER DENNIS

10% Owner

Transactions

Sale
Common Stock
2012-05-29$0.30/sh−15,300$4,622→ 3,901,997 total(indirect: See Footnote)
Sale
Common Stock
2012-05-23$0.30/sh−135,250$40,629→ 4,210,312 total(indirect: See Footnote)
Sale
Common Stock
2012-05-25$0.30/sh−293,015$87,905→ 3,917,297 total(indirect: See Footnote)
Sale
Common Stock
2012-05-30$0.30/sh−51,007$15,302→ 3,850,990 total(indirect: See Footnote)
Sale
Common Stock
2012-05-31$0.30/sh−29,850$8,955→ 3,821,140 total(indirect: See Footnote)
Sale
Common Stock
2012-05-22$0.30/sh−287,000$86,990→ 4,345,562 total(indirect: See Footnote)

SIMON NICHOLAS J III

10% Owner

Transactions

Sale
Common Stock
2012-05-29$0.30/sh−15,300$4,622→ 3,901,997 total(indirect: See Footnote)
Sale
Common Stock
2012-05-25$0.30/sh−293,015$87,905→ 3,917,297 total(indirect: See Footnote)
Sale
Common Stock
2012-05-31$0.30/sh−29,850$8,955→ 3,821,140 total(indirect: See Footnote)
Sale
Common Stock
2012-05-30$0.30/sh−51,007$15,302→ 3,850,990 total(indirect: See Footnote)
Sale
Common Stock
2012-05-22$0.30/sh−287,000$86,990→ 4,345,562 total(indirect: See Footnote)
Sale
Common Stock
2012-05-23$0.30/sh−135,250$40,629→ 4,210,312 total(indirect: See Footnote)

GADICKE ANSBERT

10% Owner

Transactions

Sale
Common Stock
2012-05-30$0.30/sh−51,007$15,302→ 3,850,990 total(indirect: See Footnote)
Sale
Common Stock
2012-05-23$0.30/sh−135,250$40,629→ 4,210,312 total(indirect: See Footnote)
Sale
Common Stock
2012-05-29$0.30/sh−15,300$4,622→ 3,901,997 total(indirect: See Footnote)
Sale
Common Stock
2012-05-31$0.30/sh−29,850$8,955→ 3,821,140 total(indirect: See Footnote)
Sale
Common Stock
2012-05-25$0.30/sh−293,015$87,905→ 3,917,297 total(indirect: See Footnote)
Sale
Common Stock
2012-05-22$0.30/sh−287,000$86,990→ 4,345,562 total(indirect: See Footnote)

WHEELER KURT

Director

Transactions

Sale
Common Stock
2012-05-25$0.30/sh−293,015$87,905→ 3,917,297 total(indirect: See Footnote)
Sale
Common Stock
2012-05-30$0.30/sh−51,007$15,302→ 3,850,990 total(indirect: See Footnote)
Sale
Common Stock
2012-05-23$0.30/sh−135,250$40,629→ 4,210,312 total(indirect: See Footnote)
Sale
Common Stock
2012-05-29$0.30/sh−15,300$4,622→ 3,901,997 total(indirect: See Footnote)
Sale
Common Stock
2012-05-31$0.30/sh−29,850$8,955→ 3,821,140 total(indirect: See Footnote)
Sale
Common Stock
2012-05-22$0.30/sh−287,000$86,990→ 4,345,562 total(indirect: See Footnote)

EVNIN LUKE

10% Owner

Transactions

Sale
Common Stock
2012-05-30$0.30/sh−51,007$15,302→ 3,850,990 total(indirect: See Footnote)
Sale
Common Stock
2012-05-23$0.30/sh−135,250$40,629→ 4,210,312 total(indirect: See Footnote)
Sale
Common Stock
2012-05-22$0.30/sh−287,000$86,990→ 4,345,562 total(indirect: See Footnote)
Sale
Common Stock
2012-05-29$0.30/sh−15,300$4,622→ 3,901,997 total(indirect: See Footnote)
Sale
Common Stock
2012-05-25$0.30/sh−293,015$87,905→ 3,917,297 total(indirect: See Footnote)
Sale
Common Stock
2012-05-31$0.30/sh−29,850$8,955→ 3,821,140 total(indirect: See Footnote)

STEINMETZ MICHAEL

10% Owner

Transactions

Sale
Common Stock
2012-05-25$0.30/sh−293,015$87,905→ 3,917,297 total(indirect: See Footnote)
Sale
Common Stock
2012-05-23$0.30/sh−135,250$40,629→ 4,210,312 total(indirect: See Footnote)
Sale
Common Stock
2012-05-31$0.30/sh−29,850$8,955→ 3,821,140 total(indirect: See Footnote)
Sale
Common Stock
2012-05-22$0.30/sh−287,000$86,990→ 4,345,562 total(indirect: See Footnote)
Sale
Common Stock
2012-05-29$0.30/sh−15,300$4,622→ 3,901,997 total(indirect: See Footnote)
Sale
Common Stock
2012-05-30$0.30/sh−51,007$15,302→ 3,850,990 total(indirect: See Footnote)

Footnotes (12)

[F1]The shares were sold as follows: 239,235 by MPM BioVentures III-QP, L.P. ("BV III QP"), 16,086 by MPM BioVentures III, L.P. ("BV III"), 4,236 by MPM Asset Management Investors 2005 BVIII LLC ("AM 2005"), 7,227 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 20,216 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"). MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III, BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM III LLC and the managers of AM 2005.
[F10]The shares are held as follows: 3,210,050 by BV III QP, 215,848 by BV III, 56,863 by AM 2005, 96,966 by BV Parallel and 271,263 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F11]The shares were sold as follows: 24,882 by BV III QP, 1,673 by BV III, 440 by AM 2005, 752 by BV Parallel and 2,103 by BV KG.
[F12]The shares are held as follows: 3,185,168 by BV III QP, 214,175 by BV III, 56,423 by AM 2005, 96,214 by BV Parallel and 269,160 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F2]The shares are held as follows: 3,622,311 by BV III QP, 243,568 by BV III, 64,163 by AM 2005, 109,419 by BV Parallel and 306,101 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F3]The shares were sold as follows: 112,740 by BV III QP, 7,581 by BV III, 1,996 by AM 2005, 3,406 by BV Parallel and 9,527 by BV KG.
[F4]The shares are held as follows: 3,509,571 by BV III QP, 235,987 by BV III, 62,167 by AM 2005, 106,013 by BV Parallel and 296,574 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F5]The shares were sold as follows: 244,249 by BV III QP, 16,423 by BV III, 4,325 by AM 2005, 7,378 by BV Parallel and 20,640 by BV KG.
[F6]The shares are held as follows: 3,265,322 by BV III QP, 219,564 by BV III, 57,842 by AM 2005, 98,635 by BV Parallel and 275,934 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F7]The shares were sold as follows: 12,754 by BV III QP, 857 by BV III, 226 by AM 2005, 385 by BV Parallel and 1,078 by BV KG.
[F8]The shares are held as follows: 3,252,568 by BV III QP, 218,707 by BV III, 57,616 by AM 2005, 98,250 by BV Parallel and 274,856 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F9]The shares were sold as follows: 42,518 by BV III QP, 2,859 by BV III, 753 by AM 2005, 1,284 by BV Parallel and 3,593 by BV KG.

Documents

1 file

4
c28976_4x0.xmlPrimary
MAIN DOCUMENT DESCRIPTION

Issuer

Somaxon Pharmaceuticals, Inc.

CIK 0001339455

→

Entity typeother

Related Parties

filerCIK 0001166285

Filing Metadata

Form type: 4
Filed: Jun 3, 8:00 PM ET
Accepted: Jun 4, 4:54 PM ET
Size: 24.4 KB

View on SEC.gov